Umit Tapan MD
Associate Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-7523umit.tapan@bmc.org
utapan@bu.edu
Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Evans Center for Interdisciplinary Biomedical Research
Biography
Dr. Umit Tapan is a physician-scientist who is an attending thoracic oncologist at Boston Medical Center (BMC) whose clinical interests are non-small cell lung cancer, small cell lung cancer, mesothelioma, immunotherapy and targeted therapy/precision medicine. His research interests center on reducing disparities in lung cancer treatment, improving access to new treatments. He has served as site PI at BMC for 16 therapeutic trials and currently manages seven active protocols funded by the National Cancer Institute and industry partners. Since 2019, he has served as co-director of the Thoracic Oncology Program within the BU-BMC Cancer Center, and in 2020 he was appointed director of inpatient medical operations for the section of hematology and medical oncology.
Education
MD, Hacettepe University
Publications
Dirnberger F, Patel S, Boyne DJ, Lan Z, Uyei J, Wang J, Cho S, DeCosta L, Bridges IM, Tapan U. Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer. Adv Ther. 2026 Jun 30. PMID: 42377743.
Published on 6/18/2026Ferri GM, Murphy JF, Oza A, Bulteel AJB, Abbasi W, Anderson R, Dinc MT, Gaufberg E, Cengiz K, Sontha S, Weinberg J, Kurpaska P, Mangala YO, Kulke M, Tapan U. Safety of immune checkpoint inhibitors in a diverse patient population: a single-institution experience. Ecancermedicalscience. 2026; 20:2150. PMID: 42453165.
Published on 5/20/2026Hill NR, Crosbie A, Szymialis R, Botros A, Zhang Y, Tapan U. Impact of social determinants of health on treatment patterns and outcomes in metastatic non-small cell lung cancer. J Oncol Pharm Pract. 2026 May 20; 10781552261449764. PMID: 42159393.
Published on 3/10/2026Kim JY, Dirks A, Ford RM, Pai L, Ludwig C, Tapan U. How exclusion criteria can hinder eligibility for lung cancer studies among different racial and ethnic groups. PLOS Digit Health. 2026 Mar; 5(3):e0001262. PMID: 41805924.
Published on 1/24/2026Martinez CB, Bhatt S, Battaglini J, Beckett A, Tapan U. Lung Cancer in the Incarcerated Population: A Narrative Review. Curr Oncol Rep. 2026 Jan 24; 28(1):2. PMID: 41579227.
Published on 1/3/2026Battaglini J, AlDoughaim M, Li K, Patel J, Bhatt S, Everett P, Oxnard GR, Tapan U. Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer. Clin Transl Oncol. 2026 Jun; 28(6):2428-2434. PMID: 41484568.
Published on 9/1/2025Wang J, Sajeev G, Chai X, Takundwa R, Dirnberger F, Pundole X, Pastel M, Yang H, Tapan U. Efficacy outcomes between tarlatamab and real-world physicians' choice of therapies for previously treated extensive stage small cell lung cancer. Oncologist. 2025 Sep 01; 30(9). PMID: 40839303.
Published on 8/29/2025Shah MV, Solem CT, Liao A, Bell KF, Wang Y, Yang H, Meng Y, Ye M, Tapan U. Patient and Physician Preferences for Maintenance Treatment in Advanced Non-Small Cell Lung Cancer: Insights into Treatment Selection. Adv Ther. 2025 Nov; 42(11):5499-5514. PMID: 40879895.
Published on 4/15/2025Shah MV, Solem CT, Bell KF, Aziez A, Sun X, Du M, Du EX, Yang H, Wang H, Hua Q, Tapan U. Real-World Maintenance Treatment Patterns Among Patients with Advanced Non-Small Cell Lung Cancer. Adv Ther. 2025 Jun; 42(6):2782-2796. PMID: 40232624.
Published on 3/10/2025Radwan A, Jani CT, Al Omari O, Patel M, Burns L, Mackay Z, Li L, Mahdaviani K, Davidson A, Weinberg J, Everett PC, Suzuki K, Mak KS, Kulke MH, Tapan U. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. Oncologist. 2025 Mar 10; 30(3). PMID: 39603266.
Media Mentions
Published on 10/18/2024
Expanding Access to NSCLC Innovations: Challenges and Opportunities
Published on 2/9/2022
Racial, Socioeconomic Disparities in Extensive-Stage Small Cell Lung Cancer Treatment
Published on 2/16/2021
Published on 11/16/2020
Racial and Other Disparities Persist Among Patients with Extensive-Stage Small Cell Lung Cancer
Published on 11/2/2020
Study Finds Racial and Socioeconomic Disparities in Chemo Treatment for ES-SCLC
Published on 10/27/2020
Quality Data, Genetic Testing Can Reduce Cancer Care Disparities
Published on 10/27/2020
US healthcare: Black people less likely to receive lung cancer chemotherapy
View full list of 7 media mentions.